DRUGS IN EMOTIONAL DISORDERS: PAST AND PRESENT
Authors: L E HOLLISTER
Journal: Annals of Internal Medicine (1959)

Article1 November 1959DRUGS IN EMOTIONAL DISORDERS: PAST AND PRESENTLEO E. HOLLISTER, M.D., F.A.C.P.LEO E. HOLLISTER, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-51-5-1032 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWidespread interest in drugs currently used for treating emotional disorders has created the erroneous impression that pharmacologic approaches to psychiatric treatment are something new. Both the number and the variety of drugs employed in the past have been large. The present review will cover only those agents used for functional emotional disorders within the last 20 years, first considering briefly the older treatments. The fact that each of these has been described as ameliorating the course of emotional illness emphasizes the difficulty of evaluating such treatment. This aspect of drug therapy is still unchanged.The second purpose of this review...Bibliography1. KubanekRowell JLRC: The use of Dilantin in the treatment of psychotic patients unresponsive to other treatment, Dis. Nerv. System 7: 47-50, 1946. MedlineGoogle Scholar2. Samuels AS: Phenergan in treatment of psychiatric patients, Dis. Nerv. System 18: 183-188, 1957. MedlineGoogle Scholar3. SchlanUnna LSKR: Some effects of Myanesin in psychiatric patients, J. A. M. A. 104: 672-673, 1949. CrossrefGoogle Scholar4. FrankMcGraw JARB: Carbon dioxide therapy: a clinical evaluation of 200 patients, J. Nerv. and Ment. Dis. 123: 563-567, 1956. CrossrefMedlineGoogle Scholar5. SacklerSacklervan OphuijsenTuiSackler RRMDHWCAM: An appraisal of the current status of histamine biochemotherapy in psychiatry and the theoretical significance of its effects. Endocrinologic orientation to psychiatric disorders, J. Clin. and Exper. Psychopath. 12: 5-13, 1951. MedlineGoogle Scholar6. Forrer GR: Symposium on atropine toxicity therapy. History and future research, J. Nerv. and Ment. Dis. 124: 256-281, 1956. CrossrefMedlineGoogle Scholar7. De M. Rudolf G: The treatment of depression with desoxyephedrine (Methedrine), J. Ment. Sc. 95: 920-929, 1949. CrossrefGoogle Scholar8. DavidoffGoodstone EGL: The amphetamine-barbiturate therapy in psychiatric conditions, Psychiatric Quart. 16: 541-548, 1942. CrossrefGoogle Scholar9. ParkerWrigley DSF: Synthetic cannabis preparations in psychiatry: Synhexyl, J. Ment. Sc. 96: 276-279, 1950. CrossrefGoogle Scholar10. LevineRinkelGreenblatt JMM: Psychological and physiological effects of intravenous Pervitin, Am. J. Psychiat. 105: 429-434, 1948. CrossrefMedlineGoogle Scholar11. WedgeMoulton BM: A method of pharmacologic facilitation of psychiatric investigation, J. Nerv. and Ment. Dis. 3: 116-121, 1950. CrossrefGoogle Scholar12. BurschJohnson AKWC: LSD-25 as an aid in psychotherapy. Preliminary report of a new drug, Dis. Nerv. System 11: 241-243, 1950. MedlineGoogle Scholar13. RockwellDiethelm FVO: Dibenamine therapy in certain Psychopathologic syndromes, Tr. Am. Neurol. A. 73: 127-131, 1948. MedlineGoogle Scholar14. KralKrauser VAWG: Psychiatric experiences with Plexonal, Canad. M. A. J. 70: 453-455, 1954. MedlineGoogle Scholar15. Chlorpromazine and mental health, Symposium, 1955, Lea and Febiger, Philadelphia. Google Scholar16. Miner RW, editor: Symposium: Reserpine in the treatment of neuropsychiatric, neurological, and related clinical conditions, Ann. New York Acad. Sc. 61: 1-280, 1955. MedlineGoogle Scholar17. St. Whitelock OV, editor: Symposium: Meprobamate and other agents used in mental disturbances, Ann. New York Acad. Sc. 67: 671-894, 1957. Google Scholar18. Himwich HE: Psychopharmacologic drugs, Science 127: 59-72, 1958. CrossrefMedlineGoogle Scholar19. Hollister LE: The present status of tranquilizing drugs, California Med. 89: 1-6, 1958. MedlineGoogle Scholar20. Hollister LE: Complications from the use of tranquilizing drugs, New England J. Med. 257: 170-177, 1957. CrossrefMedlineGoogle Scholar21. Wikler A: The relation of psychiatry to pharmacology, American Society for Pharmacology and Experimental Therapeutics, 1957, The Williams and Wilkins Co., Baltimore. Google Scholar22. Smith JA: The use of the isopropyl derivative of isonicotinylhydrazine (Marsilid) in the treatment of mental disease; a preliminary report, Am. Pract. and Digest Treat. 4: 519-520, 1953. MedlineGoogle Scholar23. Sackler M, editor: Symposium on the biochemical and clinical aspects of Marsilid and other monoamine oxidase inhibitors, J. Clin. and Exper. Psychopath. 19 (supplement 1): 1-186, 1958. MedlineGoogle Scholar24. St. Whitelock OV: Symposium on monoamine oxidase inhibitors, Ann. New York Acad. Sc., in press. Google Scholar25. Kuhn R: The treatment of depressive states with an iminodibenzyl derivative (G 22355), Schweiz. med. Wchnschr. 87: 1135-1140, 1957. MedlineGoogle Scholar26. LehmannCahndeVerteuil HECHRL: The treatment of depressive conditions with imipramine (G 22355), Canad. Psychiat. A. J. 3: 155-164, 1958. MedlineGoogle Scholar27. LemereLasater FJH: Deanol (Deaner) a new cerebral stimulant for the treatment of neurasthenia and mild depression: a preliminary report, Am. J. Psychiat. 114: 655-656, 1958. CrossrefMedlineGoogle Scholar28. Stoll WA: LSD, a hallucinatory agent from the ergot group, Schweiz. Arch. Neurol. u. Psychiat. 60: 1-45, 1947. Google Scholar29. BerlinGuthrieWeiderGoodellWolff LTAHHG: Studies in human cerebral function. The effects of mescaline and lysergic acid on cerebral processes pertinent to creative activity, J. Nerv. and Ment. Dis. 122: 407-491, 1955. CrossrefGoogle Scholar30. OstfeldVisotskyAboodLebovitz AMHLBZ: Studies with a new hallucinogen. Some dosage-response tests for JB-318, Arch. Neurol. and Psychiat. 81: 256-263, 1959. CrossrefGoogle Scholar31. St. Whitelock OV, editor: Symposium. Pharmacology of psychotomimetic and psychotherapeutic drugs, Ann. New York Acad. Sc. 66: 417-840, 1957. Google Scholar32. Koelle GB: The pharmacology of mescaline and d-lysergic acid diethylamide (LSD), New England J. Med. 258: 25-32, 1958. CrossrefMedlineGoogle Scholar33. ElderGogertyDille JTJHJM: Survey of d-lysergic acid diethylamide (LSD) antagonists, Federation Proc. 16: 293, 1957. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Palo Alto, California*Received for publication June 1, 1959.From the Medical Service, Veterans Administration Hospital, Palo Alto, California.Requests for reprints should be addressed to Leo E. Hollister, M.D., Chief, Medical Service, Veterans Administration Hospital, Palo Alto, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPhenothiazine BibliographiesPhenothiazine und Azaphenothiazine als HeilmittelPoisoning by Organic Phosphorus Pesticides Potentiated by Phenothiazine DerivativesMedical Management of Mental Problems in the AgedThe Physician as a Therapeutic AgentPROBABLE HEPATIC ALLERGY TO CHLORPROMAZINE AND DELIBERATE DESENSITIZATION*LEO WAITZKIN, M.D. 1 November 1959Volume 51, Issue 5Page: 1032-1048KeywordsAmphetaminesChlorpromazineDrug therapyDrugsEmotionsHormonesMedical servicesPsychosesReserpine ePublished: 1 December 2008 Issue Published: 1 November 1959 PDF downloadLoading ...